Categories
World News

Traders react to Fed resolution

A forex trader monitors exchange rates in a trading room at KEB Hana Bank in Seoul on March 13, 2020.

YOUNG YEON-JE | AFP via Getty Images

SINGAPORE – Stocks in Japan and South Korea rose on Thursday as investors reacted after the Federal Reserve’s political committee decided to keep short-term lending rates near zero at a widely anticipated pace.

Japan’s Nikkei 225 rose 1.4% while the Topix index rose 0.93%. The South Korean Kospi rose 1.17% and the Kosdaq rose 0.83%.

Australian stocks hovered between gains and losses, with the benchmark ASX 200 index down 0.26% as most sectors traded lower. However, the energy and materials sub-indices rebounded from losses in the previous session, rising 0.59% and 0.45%, respectively.

US stocks rose overnight, pushing the Dow Jones Industrial Average to its first close above 33,000, while government bond yields fell from previous highs.

Fed decision

The Fed raised its expectations for economic growth, but stated that there will likely be no rate hikes until 2023.

Chairman Jerome Powell said he expected inflation to rise this year, partly due to weak year-on-year comparisons from the early days of the Covid-19 pandemic in 2020. However, he said that this will not be enough to change the policy aimed at inflation over a period of over 2% for any period if it helps to achieve full and inclusive employment.

Four of the 18 members of the Federal Open Market Committee were looking for a rate hike in 2022, compared to just one at the December meeting, according to the “scatter chart” of each member’s forecast. Seven members are seeing a hike in 2023, compared to five in December.

The members of the FOMC forecast quarterly where interest rates will go in the short, medium and long term. These projections are graphed visually and are known as a scatter plot.

“The FOMC statement was very similar to the January one,” Commonwealth Bank of Australia strategists wrote in a note Thursday morning. “The committee noted, however, that activity and employment indicators have risen recently. Nonetheless, the statement maintained that the ongoing health crisis continues to pose” significant risks to the economic outlook “and that current levels of policy arrangements are appropriate remains.”

“The combination of unchanged median dot plots and the reluctant comments from Chair Powell depressed USD and US bond yields (after yields rose earlier in the day),” noted the CBA strategists.

Currencies and oil

In the forex market, the dollar fell against a basket of competitors as the dollar index fell from near 91.900 prior to the Fed’s decision to around 91.371 Thursday morning during Asian trading hours.

The Japanese yen changed hands at $ 108.92 a dollar while the Australian dollar rose 0.44% to $ 0.7828.

Oil prices barely moved during Asian trading hours on Thursday. US crude oil futures were slightly lower at $ 64.54 while the global benchmark Brent index fell 0.1% to $ 67.93.

Energy prices fell overnight on mounting fuel demand concerns and rising US inventories. In Europe, there are concerns that economic recovery could be delayed after several countries temporarily stopped using AstraZeneca’s Covid-19 vaccines due to concerns about possible side effects.

– CNBC’s Jeff Cox contributed to this report.

Categories
Health

Docs react as EU international locations droop shot

A healthcare worker prepares a syringe with the dose of AstraZeneca Covid-19 in Coria City Hospital, Spain.

Gustavo Valiente | SOPA pictures | LightRocket via Getty Images

LONDON – Health professionals are disappointed and confused about the numerous suspensions of the coronavirus vaccine developed by AstraZeneca and Oxford University. They warn that there is not enough data to justify these decisions.

Germany, France, Italy and Spain joined a rapidly growing list of European countries on Monday that are stopping use of the vaccine as a precautionary measure after reports of blood clots.

Other countries such as Austria have temporarily stopped using certain lots of the Oxford-AstraZeneca vaccine. Thailand became the first Asian nation on Friday to stop using the shot because of safety concerns.

The UK, Canada and Australia, which continue to use the vaccine, are among the countries trying to reassure citizens about its benefits.

The World Health Organization, the European Medicines Agency and the International Society on Thrombosis and Hemostasis have recommended that countries continue to use the Oxford-AstraZeneca vaccine.

There is still no evidence of data to really justify these decisions.

Michael Head

Senior Research Fellow in Global Health at the University of Southampton

“The decisions made by France, Germany and other countries look amazing,” said Dr. Michael Head, Senior Research Fellow in Global Health at the University of Southampton, UK

“The data we have suggests that the number of blood clot-related adverse events is the same (and possibly fewer) in vaccinated groups compared to non-vaccinated populations,” he continued.

“Pausing the introduction of a vaccine during a pandemic has consequences. This creates delays in protecting people and a possible delay in vaccine due to people who have seen the headlines and are understandably concerned. There is still no evidence of data that really justify these decisions, “added Head.

WHO experts will meet on Tuesday to review the safety of the shot.

The European Medicines Agency, which also evaluates the drug’s safety, says there is no evidence that it causes blood clots and believes the benefits of the vaccine “continue to outweigh the risks”.

What did AstraZeneca say?

More than 17 million people in the European Union and the United Kingdom have received a dose of the Oxford AstraZeneca vaccine. As of last week, fewer than 40 cases of blood clots had been reported, AstraZeneca said in a statement.

The pharmaceutical company said that 15 events involving deep vein thrombosis and 22 events involving pulmonary embolism were reported among those vaccinated in the EU and the United Kingdom.

“This is much less than expected to occur naturally in a general population of this size, and it is similar to other approved COVID-19 vaccines,” said AstraZeneca.

The EMA has also said that the data available so far showed that the number of blood clots in vaccinated people is no higher than in the general population.

A bottle of the AstraZeneca vaccine.

Igor Petyx | KONTROLAB | LightRocket via Getty Images

Europe’s caution regarding the drug has exacerbated the problems of the battered vaccination campaign in the region and comes at a time when the German health department has warned that a third wave of coronavirus infections has already begun.

Dr. Stephen Griffin, associate professor in the University of Leeds School of Medicine, said the news that many countries in Europe had suspended the introduction of the Oxford-AstraZeneca vaccine was “disappointing”.

“With many European countries currently experiencing a resurgence of SARS-CoV2 infections and still lagging behind on adoption, the importance of continuing vaccination programs and the harm done by people having access to one should not be underestimated Vaccine denied will do. ” even the worst-case scenarios probably outweigh the odds, if at some point a connection to the coagulation disorders is found, “said Griffin.

“It should also be noted that nationwide gestures like these inevitably create hesitation or a more extreme sentiment towards vaccines and further undermine vaccination efforts,” he added.

How does the vaccine work?

The Oxford AstraZeneca vaccine is designed to prevent coronavirus in people aged 18 and over. It’s made up of an adenovirus that has been modified to contain the gene to make a protein from SARS-CoV-2, the virus that causes Covid-19. Therefore, the vaccine does not contain a virus and cannot cause Covid.

The most common side effects of the shot are typically mild or moderate and get better within a few days after vaccination.

In late clinical studies, the AstraZeneca Oxford shot was found to have an average of 70% effectiveness in protecting against the virus.

“We are carefully reviewing the reports, but the evidence available does not suggest that the vaccine is the cause,” said Dr. Phil Bryan, Vaccine Safety Director for the UK Medicines and Health Products Regulatory Agency.

“Blood clots can occur naturally and are not uncommon. In the UK, more than 11 million doses of the AZ vaccine have now been given and the number of blood clots reported after the vaccine is no more than the number that would have occurred naturally in the UK of the vaccinated population, “he continued.

“We are working closely with international colleagues to understand the global safety experience of COVID-19 vaccines and to share safety data and reports quickly. People should still get their COVID-19 vaccine when prompted,” said Bryan.